Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Seres Therapeutics (MCRB) Depreciation and Depletion (2023 - 2024)

Seres Therapeutics (MCRB) has disclosed Depreciation and Depletion for 2 consecutive years, with $333000.0 as the latest value for Q3 2024.

Quarterly Depreciation and Depletion changed N/A to $333000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $989000.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $989000.0 for FY2024, 51.02% down from the prior year.
Depreciation and Depletion hit $333000.0 in Q3 2024 for Seres Therapeutics, up from $328000.0 in the prior quarter.
In the past five years, Depreciation and Depletion ranged from a high of $551000.0 in Q4 2023 to a low of $328000.0 in Q1 2024.